Physician profile
Vikas K Rathi
NPI 1194927962
$1,646.95
in general payments reported to CMS, 2019-2025
22 companies · $422 in 2025
The $422 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $165 · 2021: $246 · 2022: $65.84 · 2023: $67.30 · 2024: $294 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $782.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $287.97 | 2019-2024 | |
| Boston Scientific Corporation | $205.71 | 2019-2025 | Avvigo Guidance System |
| Heartflow, INC. | $196.44 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.73 | 2020-2022 | |
| Medtronic, INC. | $159.69 | 2021-2025 | Corevalve Evolut R |
| Biosense Webster, INC. | $100.99 | 2024 | Carto 3 |
| Medtronic Vascular, INC. | $98.59 | 2019 | |
| Astellas Pharma US INC | $92.10 | 2019-2021 | |
| Ge Healthcare | $48.80 | 2025 | |
| Novartis Pharmaceuticals Corporation | $45.66 | 2021 | |
| Amgen INC. | $35.11 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $31.48 | 2023 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $24.00 | 2024 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $21.35 | 2021 | |
| Atricure, INC. | $19.70 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $19.50 | 2023 | Renasys Go V2 Home, Pico |
| Medicomp INC | $19.24 | 2024 | Telepatch Cardiac Monitor |
| Lantheus Medical Imaging, INC. | $17.69 | 2020 | |
| Alnylam Pharmaceuticals INC. | $16.32 | 2023 | Onpattro |
| Cardiva Medical, INC. | $14.49 | 2019 | |
| Gilead Sciences, INC. | $13.86 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Rathi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.